Global prevalence of sexual dysfunction among women with metabolic syndrome: a systematic review and meta-analysis

Nader Salari; Mona Moradi; Amin Hosseinian Far; Yassaman Khodayari; Masoud Mohammadi

doi:10.1007/s40200-023-01267-5

Global prevalence of sexual dysfunction among women with metabolic syndrome: a systematic review and meta-analysis

Nader Salari
, Mona Moradi
, Amin Hosseinian Far
, Yassaman Khodayari
, Masoud Mohammadi^*

^*Corresponding author for this work

Business Systems & Operations

Research output: Contribution to Journal › Review Article › peer-review

Abstract

Sexual dysfunction is a common disorder among women, especially during menopause. Metabolic syndrome is a multifactorial disease that, according to previous studies, there is a relationship between the metabolic syndrome and sexual dysfunction among women. The aim of this systematic review and meta-analysis is to obtain the prevalence of Female Sexual Dysfunction (FSD) among women with metabolic syndrome, and to analyze available related evidence. In this systematic review and meta-analysis, the keywords of MeSH, female sexual dysfunction, FSD, metabolic syndrome were searched in PubMed, Web of Science, Scopus, Science Direct and Google Scholar. The searches were conducted without a lower time limit and until May 2022. The prevalence of FSD among women with metabolic syndrome was found to be 39.3% (95% CI: 28.3-51.5). In the subgroup analysis and in the review of 4 studies, the prevalence of sexual dysfunction in postmenopausal women with metabolic syndrome was 49.8% (95% CI: 26.1-73.6). Analyzing the results of the meta-regression test in examining the effect of the three factors of sample size, year of the study, age, and BMI of the patients on the heterogeneity of the meta-analysis, showed that with the increase of the sample size, the prevalence of sexual dysfunction among women with metabolic syndrome decreases (

Original language	English
Pages (from-to)	1011-1019
Number of pages	9
Journal	Journal of Diabetes and Metabolic Disorders
Volume	22
Issue number	2
DOIs	https://doi.org/10.1007/s40200-023-01267-5
Publication status	Published - 28 Jul 2023

Bibliographical note

© The Author(s), under exclusive licence to Tehran University of Medical Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BMI
FSD
Female sexual dysfunction
Meta-analysis
Metabolic syndrome

Access to Document

10.1007/s40200-023-01267-5

https://link.springer.com/article/10.1007/s40200-023-01267-5#article-info

Cite this

@article{e93ab20ababf4ff7ada5d7e05f888083,

title = "Global prevalence of sexual dysfunction among women with metabolic syndrome: a systematic review and meta-analysis",

abstract = "Sexual dysfunction is a common disorder among women, especially during menopause. Metabolic syndrome is a multifactorial disease that, according to previous studies, there is a relationship between the metabolic syndrome and sexual dysfunction among women. The aim of this systematic review and meta-analysis is to obtain the prevalence of Female Sexual Dysfunction (FSD) among women with metabolic syndrome, and to analyze available related evidence. In this systematic review and meta-analysis, the keywords of MeSH, female sexual dysfunction, FSD, metabolic syndrome were searched in PubMed, Web of Science, Scopus, Science Direct and Google Scholar. The searches were conducted without a lower time limit and until May 2022. The prevalence of FSD among women with metabolic syndrome was found to be 39.3\% (95\% CI: 28.3-51.5). In the subgroup analysis and in the review of 4 studies, the prevalence of sexual dysfunction in postmenopausal women with metabolic syndrome was 49.8\% (95\% CI: 26.1-73.6). Analyzing the results of the meta-regression test in examining the effect of the three factors of sample size, year of the study, age, and BMI of the patients on the heterogeneity of the meta-analysis, showed that with the increase of the sample size, the prevalence of sexual dysfunction among women with metabolic syndrome decreases ( ",

keywords = "BMI, FSD, Female sexual dysfunction, Meta-analysis, Metabolic syndrome",

author = "Nader Salari and Mona Moradi and \{Hosseinian Far\}, Amin and Yassaman Khodayari and Masoud Mohammadi",

note = "{\textcopyright} The Author(s), under exclusive licence to Tehran University of Medical Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.",

year = "2023",

month = jul,

day = "28",

doi = "10.1007/s40200-023-01267-5",

language = "English",

volume = "22",

pages = "1011--1019",

journal = "Journal of Diabetes and Metabolic Disorders",

issn = "2251-6581",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

TY - JOUR

T1 - Global prevalence of sexual dysfunction among women with metabolic syndrome: a systematic review and meta-analysis

AU - Salari, Nader

AU - Moradi, Mona

AU - Hosseinian Far, Amin

AU - Khodayari, Yassaman

AU - Mohammadi, Masoud

N1 - © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PY - 2023/7/28

Y1 - 2023/7/28

N2 - Sexual dysfunction is a common disorder among women, especially during menopause. Metabolic syndrome is a multifactorial disease that, according to previous studies, there is a relationship between the metabolic syndrome and sexual dysfunction among women. The aim of this systematic review and meta-analysis is to obtain the prevalence of Female Sexual Dysfunction (FSD) among women with metabolic syndrome, and to analyze available related evidence. In this systematic review and meta-analysis, the keywords of MeSH, female sexual dysfunction, FSD, metabolic syndrome were searched in PubMed, Web of Science, Scopus, Science Direct and Google Scholar. The searches were conducted without a lower time limit and until May 2022. The prevalence of FSD among women with metabolic syndrome was found to be 39.3% (95% CI: 28.3-51.5). In the subgroup analysis and in the review of 4 studies, the prevalence of sexual dysfunction in postmenopausal women with metabolic syndrome was 49.8% (95% CI: 26.1-73.6). Analyzing the results of the meta-regression test in examining the effect of the three factors of sample size, year of the study, age, and BMI of the patients on the heterogeneity of the meta-analysis, showed that with the increase of the sample size, the prevalence of sexual dysfunction among women with metabolic syndrome decreases (

AB - Sexual dysfunction is a common disorder among women, especially during menopause. Metabolic syndrome is a multifactorial disease that, according to previous studies, there is a relationship between the metabolic syndrome and sexual dysfunction among women. The aim of this systematic review and meta-analysis is to obtain the prevalence of Female Sexual Dysfunction (FSD) among women with metabolic syndrome, and to analyze available related evidence. In this systematic review and meta-analysis, the keywords of MeSH, female sexual dysfunction, FSD, metabolic syndrome were searched in PubMed, Web of Science, Scopus, Science Direct and Google Scholar. The searches were conducted without a lower time limit and until May 2022. The prevalence of FSD among women with metabolic syndrome was found to be 39.3% (95% CI: 28.3-51.5). In the subgroup analysis and in the review of 4 studies, the prevalence of sexual dysfunction in postmenopausal women with metabolic syndrome was 49.8% (95% CI: 26.1-73.6). Analyzing the results of the meta-regression test in examining the effect of the three factors of sample size, year of the study, age, and BMI of the patients on the heterogeneity of the meta-analysis, showed that with the increase of the sample size, the prevalence of sexual dysfunction among women with metabolic syndrome decreases (

KW - BMI

KW - FSD

KW - Female sexual dysfunction

KW - Meta-analysis

KW - Metabolic syndrome

U2 - 10.1007/s40200-023-01267-5

DO - 10.1007/s40200-023-01267-5

M3 - Review Article

C2 - 37975075

SN - 2251-6581

VL - 22

SP - 1011

EP - 1019

JO - Journal of Diabetes and Metabolic Disorders

JF - Journal of Diabetes and Metabolic Disorders

IS - 2

ER -

Global prevalence of sexual dysfunction among women with metabolic syndrome: a systematic review and meta-analysis

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this